Express Pharma

facebook
twitter
google_plus
Email

Browsing tag

onco-therapeutics

Lupin announces presentation of phase 1 data on LNP7457 (PRMT5 inhibitor) at the ASCO – Annual Meeting 2025

Home
- Drug approvals
- Nutraceuticals
- Pharma IT
- Policies
- Technology
- Logistics
- HR
- Biotech
- Startup Corner
- Business Strategies
- AYUSH
- More
Cover Story
Features
Specials
Guest Blogs
Interviews
Editor’s note
Events
- Upcoming Events
- Event Listings
Videos
Downloads
EP Dialogues
- Episode 1
- Episode 2

View Desktop Version